Aurinia Pharmaceuticals Inc. CEO Richard M. Glickman recently spoke at the Cowen and Company 37th Annual Healthcare Conference in Boston.
The company is a clinical stage biopharmaceutical business that is focused on developing and commercializing therapies that treat patients suffering from serious diseases who have a high unmet medical need.
is in the process of developing the investigational drug voclosporin, which will be used in the treatment of lupus nephritis. Lupus nephritis is inflammation of the kidney as a result of systemic lupus erythematosus. It shows a serious progression of the disease.
A webcast was recorded and can be accessed at www.auriniapharma.com.
Aurinia Pharmaceuticals CEO speaks at health care conference
Organizations in this Story
Want to get notified whenever we write about Aurinia Pharmaceuticals Inc. ?
Next time we write about Aurinia Pharmaceuticals Inc., we'll email you a link to the story. You may edit your settings or unsubscribe at any time.Sign-up for Alerts